NCT06822790Phase 3Recruiting

Long-Term Safety and Efficacy of Plozasiran in Adults With Hypertriglyceridemia

Study sponsor: Arrowhead Pharmaceuticals

Compare the available registry edits below. Primary completion is the date data collection ends for the main study measures; it does not tell you when results will be published.

Primary completion2028-07Estimated
Enrollment · participants869Estimated
Source updated2026-08-12Last update listed in the registry record
Version history

Changes to this trial

Last 12 months
Pro unlocks the full available history and CSV export. View Pro features

· 1 field changed

Planned enrollment increased by 29 participants

− Before

840 participants (planned)

+ After

869 participants (planned)

Check registry source